Progressive degeneration of neurons within the central nervous system (CNS) has a profound negative effect on the normal functions controlled by those cells and especially on the overall functioning of the individual. There are numerous neurodegenerative diseases which affect the brain including Alzheimer's disease, Parkinson's disease, Huntington's disease, etc. Degeneration of neurons in the retina, another part of the CNS, also occurs in many diseases including Age Related Macular Degeneration, Retinitis Pigmentosa, Diabetic Retinopathy, etc. Each of these neurodegenerative diseases appears to arise from unique primary defects which result in a chronic or an acute exposure of the neurons to Reactive Oxygen Intermediates (ROI). These toxic products of oxidative metabolism activate a cell suicide pathway - apoptosis. A universal goal in this area of research has been to find molecules which destroy or scavenge ROI in anticipation that the progression of these diseases can be slowed or halted. We hypothesized that specific inorganic nanoparticles, because of their activity, size (~5nm), nanoparticle status, insolubility and inorganic nature, would be able to enter cells and scavenge ROI and thereby prevent the activation of apoptosis and the death of the cells. Our preliminary data demonstrate that these specific nanoparticles can destroy ROI in test tubes, in retinal neurons in culture and can prevent ROI-mediated retinal degeneration in vivo. The overall objective of this project is to determine the pharmacokinetics (distribution and turnover) of these nanoparticles in order to test our hypothesis that they are acting by entering cells and preventing increases in ROI for as long as they are present.
Specific Aim One will ask the question: How long after injection do the nanoceria particles remain within the cells of the eye? A corollary is whether the nanoparticles are toxic at any concentration and over prolonged periods of time. Modified preparations of the nanoparticles will also be tested. Transmission electron microscopy will be used to directly detect the nanoparticles whereas the albino rat light-damage model will be used to detect the retention of their ability to protect retinal function.
Specific Aim Two will test the hypothesis that the mechanism by which the nanoceria particles function is by preventing the activation of apoptotic pathways rather than inducing other rescue pathways. Our data suggest that the nanoparticles will also be effective in inhibiting the progression of ROI-induced cell death that occurs in a variety of neurodegenerative diseases. The characterization of their pharmacokinetics in the retina is very important for validating their potential therapeutic applications in humans. The use of these inorganic nanoparticles as direct therapy for multiple diseases represents a novel strategy and suggests they may represent a unique technology. There are millions of people in the USA who have some form of neurodegenerative disease such as, Alzheimer's disease, Parkinson's disease, Dementia, Age Related Macular Degeneration, Diabetic Retinopathy, etc. Our preliminary data demonstrate that our rare earth element inorganic nanoparticles prevent Reactive Oxygen Species induced retinal degeneration in rats. Achievement of our specific aims, the characterization of the pharmacokinetics (uptake, distribution, and elimination) of these nanoparticles, is necessary for the eventual inhibition of neuronal degeneration and the preservation of mental abilities, vision, and overall physical activities in humans which are dependent on the central nervous system. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21EY018306-02
Application #
7475063
Study Section
Special Emphasis Panel (ZRG1-BCMB-S (50))
Program Officer
Neuhold, Lisa
Project Start
2007-08-01
Project End
2010-07-31
Budget Start
2008-08-01
Budget End
2009-07-31
Support Year
2
Fiscal Year
2008
Total Cost
$180,413
Indirect Cost
Name
University of Oklahoma Health Sciences Center
Department
Ophthalmology
Type
Schools of Medicine
DUNS #
878648294
City
Oklahoma City
State
OK
Country
United States
Zip Code
73117
Cai, Xue; Seal, Sudipta; McGinnis, James F (2016) Non-toxic retention of nanoceria in murine eyes. Mol Vis 22:1176-1187
Cai, Xue; Chen, Lijuan; McGinnis, James F (2015) Correlation of ER stress and retinal degeneration in tubby mice. Exp Eye Res 140:130-138
Cai, Xue; Seal, Sudipta; McGinnis, James F (2014) Sustained inhibition of neovascularization in vldlr-/- mice following intravitreal injection of cerium oxide nanoparticles and the role of the ASK1-P38/JNK-NF-?B pathway. Biomaterials 35:249-58
Wong, Lily L; Hirst, Suzanne M; Pye, Quentin N et al. (2013) Catalytic nanoceria are preferentially retained in the rat retina and are not cytotoxic after intravitreal injection. PLoS One 8:e58431
Kyosseva, Svetlana V; Chen, Lijuan; Seal, Sudipta et al. (2013) Nanoceria inhibit expression of genes associated with inflammation and angiogenesis in the retina of Vldlr null mice. Exp Eye Res 116:63-74
Cai, Xue; Sezate, Steven A; Seal, Sudipta et al. (2012) Sustained protection against photoreceptor degeneration in tubby mice by intravitreal injection of nanoceria. Biomaterials 33:8771-81
Cai, Xue; McGinnis, James F (2012) Oxidative stress: the achilles' heel of neurodegenerative diseases of the retina. Front Biosci (Landmark Ed) 17:1976-95
Kong, Li; Cai, Xue; Zhou, Xiaohong et al. (2011) Nanoceria extend photoreceptor cell lifespan in tubby mice by modulation of apoptosis/survival signaling pathways. Neurobiol Dis 42:514-23
Zhou, Xiaohong; Wong, Lily L; Karakoti, Ajay S et al. (2011) Nanoceria inhibit the development and promote the regression of pathologic retinal neovascularization in the Vldlr knockout mouse. PLoS One 6:e16733
Kong, Li; Zhou, Xiaohong; Li, Feng et al. (2010) Neuroprotective effect of overexpression of thioredoxin on photoreceptor degeneration in Tubby mice. Neurobiol Dis 38:446-55

Showing the most recent 10 out of 11 publications